Zobrazeno 1 - 10
of 123
pro vyhledávání: '"P. N. Komarov"'
Autor:
E. S. Vetrova, P. K. Karnakova, N. S. Bagaeva, K. K. Karnakova, M. O. Popova, A. A. Popova, O. A. Archakova, T. N. Komarov, I. E. Shohin
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 2, Pp 233-244 (2024)
Introduction. The use of tofacitinib as a pharmacological treatment for rheumatoid arthritis remains relevant in the light of the predicted increase in prevalence of the disease. At the same time, due to the withdrawal of several foreign pharmaceutic
Externí odkaz:
https://doaj.org/article/08cb41cc1d3d4366bc75f91b87a0fb5e
Publikováno v:
Вестник хирургии имени И.И. Грекова, Vol 182, Iss 5, Pp 52-58 (2024)
The trend towards minimally invasive and excellent cosmetic effect has affected the most difficult section of cardiac surgery – the aortic root. To date, there are various minimally invasive approach for the correction of aortic root pathol ogy, wh
Externí odkaz:
https://doaj.org/article/f94eb56851554726b14479564f55790b
Autor:
I. Dhif, O. S. Glazachev, Af. A. Bestavashvili, Ch. Sinlyan, E. P. GulyaevaSeltsovskaya, N. O. Kuznetsova, E. A. Syrkina, V. V. Smirnova, E. N. Dudnik, P. Sh. Chomakhidze, B. M. Tlisov, R. N. Komarov, F. Yu. Kopylov
Publikováno v:
Российский кардиологический журнал, Vol 29, Iss 7 (2024)
Aim. To assess the effect of intermittent hypoxic-hyperoxic exposures (IHHE) on the outcomes of on-pump cardiac surgery.Material and methods. This prospective, single-center, randomized, controlled study was conducted in 110 patients with heart valve
Externí odkaz:
https://doaj.org/article/560e930505734e76905b15b75533f4d1
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 1, Pp 216-223 (2024)
Introduction. The pandemic of the new coronavirus infection COVID-19 (Coronavirus Disease 2019) was caused by a single-stranded RNA virus SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2). Molnupiravir is an antiviral drug with act
Externí odkaz:
https://doaj.org/article/0c9385a92b744dc38d6443cdb156c4db
Autor:
T. N. Komarov, N. S. Bagaeva, K. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, V. S. Shcherbakova, K. Ya. Zaslavskaya, P. A. Bely, A. V. Taganov, I. E. Shohin
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 1, Pp 281-290 (2024)
Introduction. Favipiravir is an antiviral compound that inhibits the RNA-dependent polymerase and possesses antiviral properties against RNA viruses, including SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2). The new drug Areplivir® Zin
Externí odkaz:
https://doaj.org/article/81e416e4f0bc4b9390c264abd2533f7e
Autor:
T. N. Komarov, K. K. Karnakova, N. S. Bagaeva, O. A. Archakova, M. O. Popova, V. S. Shcherbakova, K. Ya. Zaslavskaya, P. A. Bely, I. E. Shohin
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 1, Pp 272-280 (2024)
Introduction. COVID-19 (Coronavirus disease 2019) almost 4 years after he start of the pandemic is still a significant public health problem. SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) that causes COVID-19 continues to mutate and sp
Externí odkaz:
https://doaj.org/article/e107ec5b3e7946f48b26c0a04f267d34
Autor:
P. K. Karnakova, T. N. Komarov, O. A. Archakova, D. Yu. Ivkin, E. S. Vetrova, I. I. Terninko, I. E. Shohin, I. A. Narkevich
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 1, Pp 257-271 (2024)
Introduction. Etmaben is a promising drug for the treatment of cardiovascular diseases, widely studied in preclinical studies. In order to conduct phase I clinical trials, it is necessary to develop a bioanalytical method for the quantitative determi
Externí odkaz:
https://doaj.org/article/e2625f9dbbf5438f998e1e0314663ac4
Autor:
U. D. Filonova, P. K. Karnakova, K. K. Karnakova, M. O. Popova, A. A. Popova, O. A. Archakova, T. N. Komarov, I. E. Shohin
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 1, Pp 224-240 (2024)
Introduction. Apixaban is an anticoagulant used in a number of thromboembolic diseases with an improved benefit-to-risk ratio, according to multiple clinical studies. Due to the prescription of apixaban as antithrombotic therapy in patients with COVI
Externí odkaz:
https://doaj.org/article/e2d995fb422d4a5d9994c62c3a1621d0
Autor:
V. N. Komoliatova, L. M. Makarov, A. G. Akopyan, A. N. Komarov, N. V. Aksenova, D. A. Besportochny
Publikováno v:
Российский кардиологический журнал, Vol 29, Iss 2S (2024)
Long QT syndrome (LQTS) assessment is based on the QT/ÖRR equation (the so-called Bazett's formula) and calculating the corrected QT (QTc). However, this formula reliably estimates the QT interval in the heart rate range (HR) of 60-90 bpm, which mak
Externí odkaz:
https://doaj.org/article/6f92f2aeeaf54e13be9db7e328ec7064
Autor:
A. A. Lomonosova, D. G. Gognieva, M. G. Abdullaev, A. S. Kostikova, N. N. Eroshchenko, A. A. Nartova, A. S. Silantyev, A. Yu. Suvorov, R. N. Komarov, A. N. Dzyundzya, D. Yu. Shchekochikhin, E. A. Syrkina, F. Yu. Kopylov
Publikováno v:
Российский кардиологический журнал, Vol 29, Iss 4 (2024)
Ischemic cardiovascular events (ischemic stroke, myocardial infarction) are the most common complications of cardiovascular diseases. One of the leading mechanisms of these complications is atherosclerosis. Lipids play an important role in plaque dev
Externí odkaz:
https://doaj.org/article/720910e7b8054a5ead5437ab0a499e48